MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$5K
Net Income
-$7,753K
Net Profit Margin
-155060.00%
EPS
-$4.57
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2025-12-31
2025-09-30
2025-06-30
Collaboration revenue
5
2,500
2,169
1,804
Restructuring charges
-
1,480
0
0
Research and development
5,149
4,988
6,535
7,498
General and administrative
2,422
3,117
3,337
3,516
Impairment charges
808
-
-
-
Total operating expense
8,379
9,585
9,872
11,014
Loss from operations
-8,374
-7,085
-7,703
-9,210
Interest income, net
178
367
477
599
Other income, net
476
87
82
50
Total other income (expense), net
654
454
559
649
Net loss
-7,720
-6,631
-7,144
-8,561
Net unrealized loss on marketable securities
-33
-11
-4
-46
Comprehensive loss
-7,753
-6,642
-7,148
-8,607
Basic EPS
-4.57
-3.552
-3.72
-4.46
Diluted EPS
-4.57
-3.552
-3.72
-4.46
Basic Average Shares
1,690,529
1,869,924*
1,919,441
1,917,629
Diluted Average Shares
1,690,529
1,869,924*
1,919,441
1,917,629
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$7,753K
(9.92%↑ Y/Y)
Other income, net
$476K
(852.00%↑ Y/Y)
Interest income, net
$178K
(-70.28%↓ Y/Y)
Net loss
-$7,720K
(9.82%↑ Y/Y)
Net unrealized loss
on marketable...
-$33K
(28.26%↑ Y/Y)
Total other income
(expense), net
$654K
(0.77%↑ Y/Y)
Loss from operations
-$8,374K
(9.08%↑ Y/Y)
Collaboration revenue
$5K
(-99.72%↓ Y/Y)
Total operating
expense
$8,379K
(-23.92%↓ Y/Y)
Research and development
$5,149K
(-31.33%↓ Y/Y)
General and
administrative
$2,422K
(-31.11%↓ Y/Y)
Impairment charges
$808K
Buy us a coffee
Bolt Biotherapeutics, Inc. (BOLT)
Bolt Biotherapeutics, Inc. (BOLT)